MakeMyTrip Limited ($MMYT) came under significant pressure following a damaging report from Morpheus Research, an activist short-selling firm, which leveled serious allegations against India's leading online travel agency. The report claims the company is deliberately circumventing a 2022 order from India's Competition Commission of India (CCI) by continuing to enforce price parity clauses, while simultaneously employing accounting practices that create a substantial gap between reported profitability metrics and underlying financial reality.
The Allegations: Regulatory Defiance and Financial Opacity
Morpheus Research's report centers on several interconnected concerns that strike at the heart of investor confidence in MakeMyTrip's operational integrity and compliance posture. The most serious allegation involves the company's continued use of price parity clauses—contractual provisions that restrict hotel partners from offering lower rates on competing platforms—despite explicit regulatory prohibition.
The CCI issued a definitive order in 2022 requiring MakeMyTrip to cease these practices, which are considered anti-competitive. The short-seller contends that the company has brazenly ignored this directive, continuing to enforce these restrictions and thereby maintaining artificial pricing advantages that harm consumers and competitors alike. This flagrant disregard for regulatory orders could expose the company to significant legal jeopardy, including potential penalties and reputational damage.
Beyond regulatory violations, the Morpheus report highlights substantial accounting discrepancies. The analysis identifies a $212 million gap between MakeMyTrip's adjusted profits and its International Financial Reporting Standards (IFRS) profits. This disparity suggests the company is employing aggressive accounting adjustments and exclusions to present a rosier financial picture to investors than underlying IFRS-compliant results would indicate. The use of non-GAAP metrics to obscure less favorable accounting realities is a red flag for investors seeking transparent financial representation.
Additional operational concerns raised include:
- Market share erosion to competitors in India's increasingly competitive online travel agency sector
- Customer safety failures, with allegations that the platform has failed to adequately vet hotel partners and protect users from unsafe accommodations
- Deceptive web design practices that may mislead customers regarding pricing, availability, and booking terms
Market Context: Regulatory Pressure and Competitive Headwinds
MakeMyTrip's challenges arrive amid intensifying regulatory scrutiny of India's digital economy. The CCI has become increasingly assertive in policing anti-competitive behavior among e-commerce and platform companies, issuing orders against major players and signaling zero tolerance for violations. In this environment, flagrant non-compliance with a prior CCI order represents an existential reputational risk.
The Indian online travel agency market has evolved significantly since MakeMyTrip's IPO. The company faces mounting competition from Oyo Rooms, Expedia (through various local partnerships), and emerging domestic competitors leveraging mobile-first strategies and AI-driven personalization. Market share losses—if substantiated—would indicate that MakeMyTrip is losing competitive footing despite its established market position.
The accounting practices highlighted by Morpheus Research also reflect broader concerns about the quality of earnings among high-growth technology companies. The adjustment of IFRS profits downward by such a substantial magnitude raises questions about the sustainability of reported profitability and the company's true economic performance. Investors have grown increasingly skeptical of large non-GAAP adjustments, particularly when they dramatically alter the narrative around financial health.
Customer safety and platform integrity have become focal points for regulators and consumers globally. Any credible allegations that MakeMyTrip has inadequately vetted hotel partners or obscured safety information through deceptive design would resonate poorly in an environment where consumer protection is increasingly paramount.
Investor Implications: Valuation Risk and Governance Concerns
For MakeMyTrip shareholders, these allegations create multiple layers of risk:
Regulatory and Legal Risk: Continued violation of CCI orders could result in substantial fines, mandatory operational changes, or even license restrictions. The cost of regulatory remediation and potential penalties could significantly impact near-term profitability.
Valuation Compression: If market share losses are confirmed and the accounting gap reflects genuine operational challenges rather than merely conservative accounting choices, the company's growth narrative could face material revision. This would likely trigger re-rating among growth-focused investors.
Governance and Trust Deficit: The allegations, if substantiated, would signal poor corporate governance and a willingness to prioritize short-term profits over regulatory compliance and consumer protection. This erodes investor confidence in management's credibility and decision-making judgment.
Competitive Positioning: Market share losses to better-capitalized or more agile competitors would suggest MakeMyTrip is losing its structural advantages. In a commoditized travel marketplace, this is particularly concerning.
The Morpheus report's credibility will ultimately depend on independent verification by regulators, auditors, and market participants. However, the mere existence of these allegations—coupled with their specificity regarding the CCI order violation and accounting metrics—is likely to prompt institutional investors to demand management responses, audit committee investigations, and potentially, analyst downgrades.
Investors should monitor developments closely, including any regulatory action from the CCI, updates from MakeMyTrip's audit committee, and revised financial guidance. The company faces significant pressure to restore credibility through transparent disclosures and demonstrated compliance improvements.